Properties (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
CAR T-cell therapy
|
| gptkbp:administrativeDivision |
outpatient
|
| gptkbp:approves |
gptkb:B-cell_acute_lymphoblastic_leukemia
large B-cell lymphoma |
| gptkbp:associatedWith |
CAR T-cell therapy
|
| gptkbp:clinicalTrials |
gptkb:ZUMA-4
gptkb:ZUMA-20 gptkb:ZUMA-8 gptkb:ZUMA-16 gptkb:ZUMA-15 gptkb:ZUMA-18 oncology Phase 2 remission ECOG-ACRIN E1910 JCAR017 ZUMA-1 ZUMA-7 ZUMA-10 ZUMA-11 ZUMA-12 ZUMA-13 ZUMA-14 ZUMA-17 ZUMA-19 ZUMA-2 ZUMA-3 ZUMA-5 survival benefit ZUMA-9 KITE-585 TRANSCEND-ALL ZUMA-6 |
| gptkbp:developedBy |
Novartis
|
| gptkbp:embodiment |
yes
|
| gptkbp:hasPopulation |
pediatric and young adult
|
| gptkbp:healthcare |
specific genetic markers
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tisagenlecleucel
|
| gptkbp:impact |
variable
personalized medicine cure |
| gptkbp:lastProduced |
2017
|
| gptkbp:mandates |
relapsed or refractory B-cell malignancies
|
| gptkbp:manufacturer |
patient's own T-cells
|
| gptkbp:marketedAs |
Kymriah
|
| gptkbp:offers |
high
|
| gptkbp:patentType |
yes
|
| gptkbp:regulatoryCompliance |
approved
|
| gptkbp:researchAreas |
immunotherapy
|
| gptkbp:researchFocus |
B-cell malignancies
|
| gptkbp:route |
intravenous
|
| gptkbp:runnerUp |
required
|
| gptkbp:setting |
hospital-based
|
| gptkbp:sideEffect |
cytokine release syndrome
neurological toxicities |
| gptkbp:targets |
CD19
|
| gptkbp:triggerType |
modifies T-cells
|
| gptkbp:type |
gene therapy
|